T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

DISEASE CHARACTERISTICS:

• Diagnosis of 1 of the following hematologic malignancies:
• Acute myeloid leukemia (AML), meeting 1 of the following criteria:
• In first complete remission (CR1), meeting 1 of the following criteria:
• Adverse cytogenetics with minimal residual disease detectable by flow cytometry, cytogenetic analysis, fluorescence in situ hybridization (FISH), or polymerase chain reaction (PCR), defined as 1 of the following:
• Complex karyotype [≥ 3 abnormalities]
• inv(3) or t(3;3)
• t(6;9)
• t(6;11)
• Monosomy 7
• Trisomy 8, alone or with an abnormality other than t(8;21), t(9;11), inv(16), or t(16;16)
• t(11;19) (q23;p13.1)
• Failed to achieve CR after primary induction chemotherapy
• Secondary AML
• In second or subsequent remission (CR2 or greater)
• Acute lymphoblastic leukemia, meeting 1 of the following criteria:
• In CR1, meeting 1 of the following criteria:
• Adverse cytogenetics with minimal residual disease detectable by flow cytometry, cytogenetic analysis, FISH, or PCR, defined as the following:
• Translocations involving 11q23, t(9;22), or bcr-abl rearrangement
• Failed to achieve CR after primary induction chemotherapy
• In CR2, if CR1 was < 12 months
• In CR3 or greater
• Myelodysplastic syndromes (MDS)
• INT-2 or high-risk by International Prognostic Scoring System
• No MDS with Fanconi anemia
• Chronic myelogenous leukemia (CML), meeting 1 of the following criteria:
• Accelerated phase with treatment failure after imatinib mesylate
• Blast phase
• Myeloproliferative disorders, meeting 1 of the following criteria:
• Agnogenic myeloid metaplasia with adverse-risk features, meeting at least 2 of the following criteria:
• Hemoglobin < 10 g/dL or > 10g/dL if transfusion-dependent
• WBC < 4,000/mm^3 OR > 30,000/mm^3 OR requires cytoreductive therapy to maintain WBC < 30,000/mm^3
• Abnormal cytogenetics, including +8, 12p-
• Polycythemia vera or essential thrombocythemia in transformation to secondary AML
• Myelodysplastic/myeloproliferative disease
• Chronic myelomonocytic leukemia
• Hodgkin's lymphoma or non-Hodgkin's lymphoma
• Refractory lymphoma with progressive disease during combination chemotherapy
• Relapse after OR ineligible for autologous stem cell transplantation (SCT)
• Chronic lymphocytic leukemia
• Treatment failure* after fludarabine, chlorambucil, and at least 1 other salvage regimen
• Prolymphocytic leukemia (PLL), meeting 1 of the following criteria:
• T-PLL
• Treatment failure* after alemtuzumab and at least 1 other regimen
• B-PLL
• Treatment failure* after fludarabine and at least 1 other salvage regimen
• Multiple myeloma, meeting 1 of the following criteria:
• Relapse after autologous SCT
• Plasma cell leukemia
• Adverse cytogenetics, defined as 1 of the following:
• del(13q) = 11q translocation NOTE: *Treatment failure is defined as relapse within 6 months OR failure to achieve remission
• Less than 10% blasts in bone marrow and no circulating blasts in peripheral blood for the following diagnoses:
• Primary or secondary leukemia
• Refractory anemia with excess blasts
• CML
• Other eligible diagnosis in transformation to acute leukemia
• Expected survival of approximately 1 year or less with conventional therapy
• No active CNS involvement by malignancy*
• Prior CNS involvement with no current evidence of CNS malignancy allowed NOTE: *Active CNS malignancy is defined by lymphoma: tumor mass on CT scan or leptomeningeal disease OR leukemia: blasts present on cerebrospinal fluid cytospin
• Availability of a donor who is a sibling, parent, or offspring who shares 1 full haplotype (HLA-A, -B, or -DR)
• Recipient and donor must have at least a 2-antigen disparity in either the host-versus-graft or graft-versus-host direction
• Parent or offspring donor who is mismatched for a single HLA antigen (i.e., 5/6 HLA) is allowed
• No sibling donor who is 6/6 HLA-matched OR mismatched for a single HLA antigen (i.e., 5/6 HLA)
• No unrelated donor identified in a prior or current National Marrow Donor Program registry search

PATIENT CHARACTERISTICS:

Age

• 18 to 55

Performance status

• ECOG 0-2 OR
• Karnofsky 60-100%

Life expectancy

• At least 3 months

Hematopoietic

• See Disease Characteristics
• Absolute neutrophil count ≥ 1,000/mm^3*
• Platelet count ≥ 20,0000/mm^3* (without transfusion) NOTE: *Lower values may be accepted at the discretion of the principal investigator or study chairperson if due to bone marrow involvement by malignancy

Hepatic

• ALT and AST ≤ 2.5 times upper limit of normal (ULN)*
• Bilirubin ≤ 2.5 times ULN*
• Unconjugated hyperbilirubinemia consistent with Gilbert's syndrome allowed
• No chronic active hepatitis B infection
• Hepatitis B core antibody positive allowed provided patient is surface antigen negative and has no evidence of active infection
• No hepatitis C viral infection
• Seronegative for anti-hepatitis C antibody and detectable hepatitis C viral RNA by reverse transcriptase-polymerase chain reaction assay NOTE: *Higher levels may be accepted at the discretion of the principle investigator or study chairperson if such elevations are due to liver involvement by malignancy

Renal

• Creatinine ≤ 1.5 mg/dL OR
• Creatinine clearance ≥ 50 mL/min

Cardiovascular

• LVEF ≥ 45%

Pulmonary

• DLCO ≥ 50% of expected value (corrected for blood hemoglobin level and alveolar volume)

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 1 year after study participation
• HIV negative
• No active infection not responding to antimicrobial therapy
• No psychiatric disorder that would preclude study compliance or informed consent

PRIOR CONCURRENT THERAPY:

Biologic therapy

• See Disease Characteristics
• At least 2 weeks since prior monoclonal antibody therapy

Chemotherapy

• See Disease Characteristics
• At least 2 weeks since prior systemic chemotherapy

Endocrine therapy

• Not specified

Radiotherapy

• Not specified

Surgery

• Not specified

Other

• Recovered from all prior therapy
• No administration of tyrosine kinase (TK) inhibitors, including imatinib mesylate and dasatinib, during the conditioning regimen; TK inhibitor administration may resume 28 days after transplantation